Positron Emission Tomography–Computed Tomography (PET/CT) Fusion Practice Exam

The uptake of fluorodeoxyglucose (FDG) in tumors is primarily influenced by metabolic factors, particularly insulin sensitivity and the tumor's metabolic rate. Tumors with a high metabolic rate tend to take up more FDG because they are rapidly proliferating and have an increased demand for glucose. This increased uptake is often seen in malignant tumors, as they are often more metabolically active compared to benign lesions.

Additionally, insulin sensitivity plays a critical role in glucose metabolism. In patients with higher insulin sensitivity, there tends to be a more pronounced uptake of FDG in tumor tissues due to the efficient transport of glucose, influenced by insulin action. This interaction is particularly important in certain cancers that are sensitive to insulin and glucose metabolism.

While other factors, such as patient age and gender, tumor size, the specific radiotracer used, and even the time of day when the scan is performed can impact imaging and uptake levels, they do not have the same direct and significant relationship with FDG uptake in tumors as insulin sensitivity and metabolic rate do. Hence, focus on these metabolic aspects provides a more accurate understanding of what drives FDG uptake in oncological imaging.